Cognitive aspects of schizophrenia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cognitive impairments are a central feature of schizophrenia and are present in most, if not all, cases. There are multiple domains of impairment seen and the level of severity of impairment is considerable. Impairments can be detected prior to the onset of clinical symptoms and the course of impairments involves some subtle early worsening followed by stability in most cases. Cognitive impairments are associated with functional disability, particularly in domains of vocational functioning and independence of residence. Both pharmacological and cognitive remediation interventions have been employed for the treatment of these impairments, with greater progress to date being made in cognitive remediation interventions. While much is known about cognitive impairments, treatment efforts are still in an early stage of development. WIREs Cogn Sci 2013, 4:599-608. doi: 10.1002/wcs.1253 Conflict of interest: Dr. Harvey has received consulting fees from Abbott Labs, Amgen, Boehringer Ingelheim, Genentech, Johnson and Johnson, Pharma Neuroboost, Roche Parma, Sunovion Pharma, and Takeda Pharma during the past year. For further resources related to this article, please visit the WIREs website.

Original languageEnglish
Pages (from-to)599-608
Number of pages10
JournalWiley Interdisciplinary Reviews: Cognitive Science
Volume4
Issue number6
DOIs
StatePublished - Nov 1 2013

Fingerprint

Schizophrenia
Conflict of Interest
Fees and Charges
Pharmacology
Cognitive Dysfunction
Cognitive Remediation

ASJC Scopus subject areas

  • Psychology(all)
  • Neuroscience(all)

Cite this

Cognitive aspects of schizophrenia. / Harvey, Philip D.

In: Wiley Interdisciplinary Reviews: Cognitive Science, Vol. 4, No. 6, 01.11.2013, p. 599-608.

Research output: Contribution to journalArticle

@article{bd48ff8d075c4bd49747dee70ee17b59,
title = "Cognitive aspects of schizophrenia",
abstract = "Cognitive impairments are a central feature of schizophrenia and are present in most, if not all, cases. There are multiple domains of impairment seen and the level of severity of impairment is considerable. Impairments can be detected prior to the onset of clinical symptoms and the course of impairments involves some subtle early worsening followed by stability in most cases. Cognitive impairments are associated with functional disability, particularly in domains of vocational functioning and independence of residence. Both pharmacological and cognitive remediation interventions have been employed for the treatment of these impairments, with greater progress to date being made in cognitive remediation interventions. While much is known about cognitive impairments, treatment efforts are still in an early stage of development. WIREs Cogn Sci 2013, 4:599-608. doi: 10.1002/wcs.1253 Conflict of interest: Dr. Harvey has received consulting fees from Abbott Labs, Amgen, Boehringer Ingelheim, Genentech, Johnson and Johnson, Pharma Neuroboost, Roche Parma, Sunovion Pharma, and Takeda Pharma during the past year. For further resources related to this article, please visit the WIREs website.",
author = "Harvey, {Philip D}",
year = "2013",
month = "11",
day = "1",
doi = "10.1002/wcs.1253",
language = "English",
volume = "4",
pages = "599--608",
journal = "Wiley Interdisciplinary Reviews: Cognitive Science",
issn = "1939-5078",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Cognitive aspects of schizophrenia

AU - Harvey, Philip D

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Cognitive impairments are a central feature of schizophrenia and are present in most, if not all, cases. There are multiple domains of impairment seen and the level of severity of impairment is considerable. Impairments can be detected prior to the onset of clinical symptoms and the course of impairments involves some subtle early worsening followed by stability in most cases. Cognitive impairments are associated with functional disability, particularly in domains of vocational functioning and independence of residence. Both pharmacological and cognitive remediation interventions have been employed for the treatment of these impairments, with greater progress to date being made in cognitive remediation interventions. While much is known about cognitive impairments, treatment efforts are still in an early stage of development. WIREs Cogn Sci 2013, 4:599-608. doi: 10.1002/wcs.1253 Conflict of interest: Dr. Harvey has received consulting fees from Abbott Labs, Amgen, Boehringer Ingelheim, Genentech, Johnson and Johnson, Pharma Neuroboost, Roche Parma, Sunovion Pharma, and Takeda Pharma during the past year. For further resources related to this article, please visit the WIREs website.

AB - Cognitive impairments are a central feature of schizophrenia and are present in most, if not all, cases. There are multiple domains of impairment seen and the level of severity of impairment is considerable. Impairments can be detected prior to the onset of clinical symptoms and the course of impairments involves some subtle early worsening followed by stability in most cases. Cognitive impairments are associated with functional disability, particularly in domains of vocational functioning and independence of residence. Both pharmacological and cognitive remediation interventions have been employed for the treatment of these impairments, with greater progress to date being made in cognitive remediation interventions. While much is known about cognitive impairments, treatment efforts are still in an early stage of development. WIREs Cogn Sci 2013, 4:599-608. doi: 10.1002/wcs.1253 Conflict of interest: Dr. Harvey has received consulting fees from Abbott Labs, Amgen, Boehringer Ingelheim, Genentech, Johnson and Johnson, Pharma Neuroboost, Roche Parma, Sunovion Pharma, and Takeda Pharma during the past year. For further resources related to this article, please visit the WIREs website.

UR - http://www.scopus.com/inward/record.url?scp=84885802078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885802078&partnerID=8YFLogxK

U2 - 10.1002/wcs.1253

DO - 10.1002/wcs.1253

M3 - Article

AN - SCOPUS:84885802078

VL - 4

SP - 599

EP - 608

JO - Wiley Interdisciplinary Reviews: Cognitive Science

JF - Wiley Interdisciplinary Reviews: Cognitive Science

SN - 1939-5078

IS - 6

ER -